Next Article in Journal
Is Initial Misdiagnosis Associated with Reaching Disability Milestones in Patients with Multiple Sclerosis?
Previous Article in Journal
Role of Parents in Body Mass Reduction in Children with Obesity—Adherence and Success of 1-Year Participation in an Intervention Program
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 56
Issue 4
10.3390/medicina56040169
medicina-logo
Submit to this Journal Review for this Journal Edit a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Prevalence of Helicobacter pylori Infection and Diagnostic Methods in the Middle East and North Africa Region

by
Faten A. S. Alsulaimany
1,
Zuhier A. Awan
2,
Ahmad M. Almohamady
2,
Mohammed I. Koumu
2,
Bassam E. Yaghmoor
2,
Sameh S. Elhady
3,4 and
Mahmoud A. Elfaky
3,*
1
Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia
2
Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia
3
Department of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
4
Department of Pharmacognosy, Faculty of Pharmacy, Port Said University, Port Said 42526, Egypt
*
Author to whom correspondence should be addressed.
Medicina 2020, 56(4), 169; https://doi.org/10.3390/medicina56040169
Received: 25 February 2020 / Revised: 5 April 2020 / Accepted: 6 April 2020 / Published: 9 April 2020
Versions Notes

Abstract

:
Background and Objectives:Helicobacter pylori (H. pylori) infection is common worldwide and may cause gastroduodenal complications, including cancer. In this review, we examine the prevalence and distribution of various H. pylori genotypes and the risk factors for H. pylori infection, particularly in the Middle East and North Africa (MENA) region. We also introduce different global screening methods and guidelines and compare them to those currently in use in the MENA region. Materials and Methods: We searched the Google Scholar, PubMed, and Saudi Digital Library (SDL) databases for clinical trials and articles published in English. The data collection was mainly focused on MENA countries. However, for H. pylori genotypes and diagnostic methods, studies conducted in other regions or reporting global practices and guidelines were also included to allow a comparison with those in the MENA region. We also included studies examining the prevalence of H. pylori infection in healthy participants. Results: H. pylori infection is highly prevalent in the MENA region, mainly because of the accumulation of risk factors in developing countries. Herein, we highlight a lack of good quality studies on the prevalence of various H. pylori genotypes in the MENA region as well as a need for standard diagnostic methods and screening guidelines. Due to the complications associated with H. pylori, we recommend routine screening for H. pylori infection in all gastroenterology patients admitted in the MENA region. Conclusion: Concerted effort will first be required to validate affordable, non-invasive, and accurate diagnostic methods and to establish local guidelines with adapted cut-off values for the interpretation of the test results.

1. Introduction

Helicobacter pylori (H. pylori) (also was known as Campylobacter pylori or Campylobacter pyloridis) is a gram-negative, microaerophilic bacterium with a helical, curved shape (often referred to as an S-shape). H. pylori has multiple polar-sheathed flagella, which are involved in its motility and invasion mechanisms [1,2,3]. In animals, Bizzozero [4,5] was probably first in the second part of the 19th century to report the presence of such organisms in the gastrointestinal tract. He was the first person who observed and described spiral organisms in the stomach of dogs.
A century ago, Jaworski [6,7] at Cracow University detected a spiral bacteria named Vibrio rugula, in the sediment after gastric washing from patients with gastric cancer (GC) and over a quarter of century since Marshall and Warren drew attention to the spiral bacteria, Helicobacter pylori, as a pathogen in various gastric diseases. In the 1984, H. pylori was isolated and cultured by Robin Warren and Barry Marshall [8]. H. pylori is found primarily in the human gastric mucosa, its natural habitat, where it remains close to epithelial cells. Indeed, H. pylori is attracted to the gastric mucus layer, which offers cover and protection from the high acidity in the stomach and promotes better cell motility [9].
Numerous studies have shown that H. pylori infection is the leading bacterial cause of both malignant and non-malignant gastroduodenal diseases and is also involved in extra-gastroduodenal disorders. Among these, the most common disorders are peptic and duodenal ulceration, acute and chronic gastritis (which may lead to atrophic gastritis), and gastric adenocarcinoma (B-cell gastric lymphoma and mucosa-associated lymphoid tissue (MALT) lymphoma) [10,11]. However, most of the risk reduction due to improved socio-economic status (even in the absence of specific preventive strategies) is thought to stem from reduced H. pylori infection rates [12]. Due to the variety of risk factors present in developing countries, infection with multiple H. pylori genotypes is highly prevalent in the Middle East and North Africa (MENA) region. There are 19 countries that are generally considered part of the MENA region according to the World Bank and the United Nations. These are Algeria, Bahrain, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Syria, Tunisia, United Arab Emirates, and Yemen.
The pattern of infection is an early childhood acquisition of H. pylori (30–50%) that reaches over 90% during adulthood in developing countries in MENA region due to the poor socioeconomic status and overcrowded conditions [13]. The data presented on the prevalence of H. pylori in the Middle East are not completely satisfactory, it does again suggest the critical role of socio-economic development in determining H. pylori prevalence, particularly in childhood. Few studies and reviews on prevalence and diagnostic methods of H. pylori in MENA region are published, therefore it is important to summarize present knowledge on H. pylori in the region. In this review, we report the prevalence and distribution of different H. pylori genotypes in the MENA region, as well as the risk factors for H. pylori infection. We also present different screening methods available for the diagnosis H. pylori infection and global guidelines, while comparing them to those currently in use in the MENA region.

2. Methods

In this review, we searched the Google Scholar, PubMed, and Saudi Digital Library (SDL) databases for about 90 studies among clinical trials, review and full research articles published in English from 1984 until 2020. The studies included in this review were primarily conducted in the countries of the MENA region. However, for H. pylori genotypes and diagnostic methods, studies conducted in other regions were also included to allow the comparison between the global practices and guidelines and those in use in the countries of the MENA region. The keywords used to interrogate the databases included “Helicobacter pylori” in combination with “prevalence,” “genotype”, “risk”, “screening”, “diagnosis”, “guidelines”, “symptoms” and “complications” as well as “world”, “global”, “Europe”, “Arab”, “Saudi”, “Middle East”, “North Africa” and other specific region or country names. All articles were assessed for pertinence before inclusion. Studies examining the prevalence of H. pylori infection in healthy participants were also included.

3. Results and Discussion

3.1. Prevalence of H. pylori Infection

Worldwide—H. pylori infection is common worldwide and can be either symptomatic or asymptomatic. A recent review, including global studies published between 2000 and 2014, examined the prevalence of H. pylori infection in various African, South American, Asian, and European general adult populations. This review showed that the prevalence of infection varied by country (18.2–60.5% in Uganda, 68.6% among pregnant women in Chile, 80% in Bolivia, 83.4% in China, 29.4–54.5% in Japan, 76.5% and 47.9% among the Yami and Han ethnic groups in Taiwan, respectively, 72.1% in Italy, and 84.2% in Poland). The authors of the review also identified several risk factors associated with H. pylori infection, including low socioeconomic status, vegetarian diet (in the Chinese study), environmental factors (e.g., contaminated or untreated water), poor health, crowded living conditions, and day care center attendance (leading to person-to-person transmission among children) [14]. Another systematic review published in 2017 compiled 184 global studies conducted between 1970 and 2016 in a total of 62 countries [15]. The selected samples were representative of the general population, and the prevalence of H. pylori infection among all participants was 48.5%. While the infection was widely spread in developing countries (70.1% in Africa, 69.4% in South America, and 66.6% in Western Asia), the prevalence was significantly lower in developed countries (24.4% in Oceania, 34.3% in Western Europe, and 37.1% in North America) [15].
MENA region—The prevalence of H. pylori infection among the countries of the MENA region varies widely ranging from 7–50% in young children and going up to 36.8–94% in adults [16]. Data about prevalence of H. pylori infection among the MENA region are summarized (Table 1).

3.2. Risk Factors for H. pylori Infection

The risk factors for H. pylori infection have been investigated in several countries of the MENA region. Age (>10 years), low socioeconomic status, low level of education, married participants, number of residents per household, bed sharing, drinking municipal or tank water, eating outside the home, living in rural areas, smoking, alcohol consumption, type 2 Diabetes Mellitus, chronically dyspeptic patients, eating raw vegetables or spicy food and having two affected parents were identified as risk factors in the majority of studies [17,28,31,34,35,38,39,40].
However, in a study conducted in Mecca, Khan et al. observed a negative correlation between the presence of antibodies for H. pylori and smoking in females (antibodies were detected in 8% and 91% of the smokers and non-smokers, respectively) [32]. Examining other risk factors, they did not find a significant association between infection and eating spicy food or drinking-water source. In the same study, they also examined a potential correlation between eating vegetables and infection but found no evidence. Indeed, this study should have considered the difference between raw and cooked vegetables, together with other dietary habits of the participants.
In another study, Bassily et al. found that a higher level of education was positively correlated with the risk of infection in mothers, even after adjusting for the age of the mother [19].
In a study conducted in Iran, the rate of infection increased with age and number of family members but was negatively correlated with the level of education and marital status [22].
Also in Mansour-Ghanaei et al. study, they established that there was no association between H. pylori infection and these and other factors, including living areas, level of education of the parents, and monthly income. [21].
While the majority of the studies included in this review did not find a significant relationship between gender and rate of infection, two studies by Soltani et al. [22] and Al-Balushi et al. [29] found that seropositivity was more widespread in male than in female participants.
Beyond general improvements in socio-economic status leading to improved health and lower H. pylori infection rates, specific local strategies are needed to further reduce the number of incident cases and deaths due to stomach cancer, and these should be tailored to each country’s risk factor profile. Targeting the risk factors that affect stomach cancer incidence and mortality (such as smoking and diet), in addition to country specific feasible and cost-effective interventions aimed at lowering H. pylori infection rates, early detection of suspected cases, and improved access to standard treatment facilities, can be among such strategies. By providing annual updates to regional and country-level stomach cancer estimates, future iterations of global burden of disease study will be useful for monitoring the success of such strategies [12].

3.3. Prevalence of H. pylori Genotypes and Their Correlation with Disease

Worldwide—In an extensive review aimed at studying the prevalence of H. pylory vacA alleles in 24 countries worldwide, Van Doorn et al. found that 89% of the strains were subtype s1a in Northern and Eastern Europe, whereas 89% were subtype s1b in Southwest Europe (Spain and Portugal) [41]. Moreover, subtypes s1a and s1b were equally prevalent in France and Italy, and nearly equally present in North America. Most of the s1 strains isolated in Middle and South America were subtype s1b, while 77% of the s1 isolates in East Asia were subtype s1c. While subtype m1 was most common in the Iberian Peninsula (86.2%), subtypes m1 and m2a were equally present across North and South America. Subtype m2b was only detected among s1c strains found in East Asia. Globally, cagA +/vacAs1 genotypes were associated with peptic ulcer disease. The presence of cagA was significantly associated with vacAs1, while vacAs1 was associated with vacAm2. Specific vacA subtype m alleles were also preferentially associated with certain diseases, with subtypes m1 and m2 more prevalent in carcinomas and peptic ulcers, respectively.
MENA region—H. pylori main virulence genes are cagA, vacA (which has multiple subtypes), and iceA. Numerous regional and global studies have highlighted consistent associations between particular genotypes and diseases: cagA and vacA (particularly subtypes s1 and m2) with gastritis; cagA, vacAs1m1, and iceA with ulcers; and cagA with cancers. However, other genotypes were only considered in a small number of studies. For example, ureA in Saudi Arabia, babA2 in Iran, dupA in Iraq and Iran, and oipA in Tunisia and Iran have all been associated with ulcers (although some studies reported inconsistent results). In addition, cagE in Iraq, Iran, and Israel, and vacAi1 in Egypt have been associated with cancer, while cagE, in combination with other genes, was also associated with non-ulcer dyspepsia in Iran [42].
In Kuwait, the study by Al-Qabandi et al. is the only included one to examine the correlation between the prevalence of H. pylori genotypes and the nationality of the patients [43]. While the overall prevalence of cagA+ strains was 53%, a significant variation was observed with a prevalence of ~41%, 25%, 75%, and 87% in patients from the Gulf region, Egypt, India, and Bangladesh, respectively. Although the statistical significance was not considered, a substantial variation was also reported for vacA subtypes. While s1 subtypes were more prevalent in patients from India and Bangladesh, s2 subtypes were more prevalent in African patients (e.g., patients from Egypt and Somalia).
In Israel, a study by Muhsen et al. examined the prevalence and correlation of H. pylori infection according to cagA phenotype among the ethnically diverse population groups of Jerusalem. A cross-sectional study was undertaken in Arab (N = 959) and Jewish (N = 692) adults, randomly selected from Israel’s national population registry in age-sex and population strata. Sera were tested for H. pylori immunoglobulin G (IgG) antibodies. Positive samples were tested for virulence IgG antibodies to recombinant cagA protein, by enzyme-linked immunosorbent assay. Multinomial regression models were fitted to examine associations of sociodemographic factors with H. pylori phenotypes. H. pylori IgG antibody sero-prevalence was 83.3% (95% confidence interval (CI) 80.0–85.5%) and 61.4% (95% CI 57.7–65.0%) among Arabs and Jews, respectively. Among H. pylori positives, the respective cagA IgG antibody sero-positivity was 42.3% (95% CI 38.9–45.8%) and 32.5% (95% CI 28.2–37.1%) [44].

3.4. Diagnostic Methods for H. pylori

The different methods available to detect H. pylori infection can be classified according to their invasiveness (invasive or noninvasive) and timing relative to treatment (before or after treatment). The choice of one method over another is based on multiple factors, including the prevalence of infection in the population, the age of the patient, and the cost of the procedure.

3.4.1. Invasive Methods

Histology: This method has the advantage of also detecting changes in the mucosa. Several studies recommend taking two biopsies each from the corpus and antrum of the stomach [45,46,47,48], but the current gold standard is the updated Sydney classification system from Dixon et al. [49], which advises collecting specimens from five or more sites including the incisura angularis. However, to date, the available studies do not demonstrate any significant advantage of the latter approach [50,51]. Moreover, the sensitivity and specificity of histology vary between 53% and 90%, depending on the physician’s experience and density of colonization [52]. It is also important to note that this method requires endoscopic intervention, which limits its use.
Fluorescent in-situ hybridization (FISH): This method can also be used to detect specific factors or features of the bacterium, such as drug resistance [53,54]. The probes most commonly used target the 16 S and 23 S rRNA genes. FISH can be used to locate H. pylori within the gastric mucosa [55]. Importantly, this method is rapid, taking only three hours to detect H. pylori and clarithromycin resistance, but is expensive and cannot be used in clinical practice.
Culture: Although this method can be less sensitive, it requires minimally-invasive procedures, such as gastric juice sampling or the string test [56,57]. When performed with the proper media and reagents, culture usually has both high sensitivity (>90%) and specificity (100%) [58]. However, both sensitivity and specificity can be affected by certain conditions (e.g., bleeding reduces the sensitivity to 40%) [59] or age (e.g., in a group of pediatric patients the sensitivity and specificity were 95.8% and 96.4%, respectively) [60]. Culture is usually used in clinical practice after two treatment failures. However, in light of the increasing rate of H. pylori treatment failure, it would be advisable to perform culture earlier (i.e., before two treatment failures) [52]. It is important to note that culture is also susceptible to variation depending on the pathologist’s experience, the specimen quality, and the transport media [61].
Polymerase chain reaction (PCR): PCR can be performed on specimens collected from both invasive and noninvasive procedures. It is often used for small samples, which contain a limited number of bacteria. PCR can also be used to detect clarithromycin resistance [62] and is even useful after a prolonged period, when culture is not applicable. However, PCR can detect DNA from both live and dead bacteria, which may produce false positive results.
Rapid urease test(RUT): RUT it based on the breakdown of urease and the resulting change in pH. The sensitivity and specificity of this method are both affected by the presence of blood, while an increased storage time of the specimen reduces the specificity. There is also a risk of false negative results when the patient takes antibiotics or suffers from a reduction of gastric acid or achlorhydria [52]. There is good availability of commercial RUTs (e.g., CLOtest, HpFast, PyloriTek), which have both high sensitivity (85–95%) and specificity (95–100%) [63]. This diagnostic method is also relatively fast, with results obtained between a few minutes and 24 h, depending on the density of bacteria.

3.4.2. Non-Invasive Methods

Serology: Among the different types of serologic test available, the most commonly used is the enzyme immunoassay (EIA). EIA has a sensitivity and specificity of 60–100%, and the quality of the test must be evaluated for each population to fix cut-off values [52]. This method should be particularly considered for patients who previously used proton pump inhibitors (PPIs), or suffered from bleeding ulcers or gastric atrophy. One drawback of serology is the persistence of antibodies even after eradication of the infection. However, the antibodies against the heat shock protein 60 (HSP60) have been shown to decline after a relatively short treatment time (one month), while a significant correlation has been observed between the level of anti-HSP60 antibodies and the histological data [64]. Importantly, serology is an affordable method and can be useful to exclude infection [65]. Serologic tests using urine or saliva samples have also been considered, but their usefulness was limited by the reduced accuracy of the results [66].
Urea breath test (UBT): This method relies on the urease activity of H. pylori, which converts ingested 13C- or 14C-labeled urea into CO2 and NH3. UBT is usually used as a follow-up method of detection after 4–6 weeks of treatment. UBT is also affordable and has both high sensitive and specific (>95% in most well-designed studies) [67]. However, UBT requires access to a nuclear medicine department and the device used to run the tests can be expensive. This method is also subject to false negative results, which can happen in patients treated with antibiotics or PPIs, and patients suffering from corpus-predominant gastritis [68]. In general, UBT is considered more sensitive than biopsies, particularly in cases of moderate or patchy distribution of bacteria. 14C-urea is radioactive, and its use is contraindicated in children, pregnant women, and probably women of childbearing age [69].
Stool antigen test (SAT): SAT is a type of EIA, and is used both for diagnosis and to assess the response to treatment of a H. pylori infection. The different SATs evaluated have shown both varying sensitivities (48.9–100%) and specificities (87–94.4%) [52]. While SATs using monoclonal antibodies are superior to SATs using polyclonal antibodies in both pre- and post-treatment conditions [70,71], SATs are comparable to UBTs in pre-treatment but inferior in post-treatment [52].

3.4.3. Guidelines for the Diagnosis of H. pylori Infection

Worldwide—According to the global guidelines, more than one positive test is required for the diagnosis of H. pylori infection, except in cases of duodenal ulcer. The World Gastroenterology Organisation (WGO) global guidelines by Hunt et al. indicated that serology is less accurate than SAT in areas with low prevalence of H. pylori infection, where a negative test result is more valuable. Indeed, false positive results were considered dangerous because they can lead to the unnecessary administration of antibiotics. Conversely, serology was considered sufficient for diagnosis in areas with high prevalence of H. pylori infection, such as the MENA region. In areas with high rates of ulcer and gastric cancer, the WGO global guidelines also recommended to adopt an empirical test-and-treat approach or to perform an initial endoscopy for gastroenterology patients, rather than initiating treatment with PPIs regardless of the underlying causes. Importantly, serologic tests detecting antibodies against the FliD protein, an essential component of bacterial flagella, demonstrated very high specificity and sensitivity (>95% against various standards) compared to other antigens. In addition to its quality, this test was affordable and was therefore considered to be an ideal tool for screening H. pylori infection in developing countries with a high prevalence [72].
In Japan, Asaka et al. added SAT to the list of noninvasive methods given in the guidelines for H. pylori diagnosis [73]. Moreover, the Second Asian Pacific Consensus guidelines for H. pylori infection indicated that SAT was an acceptable diagnostic tool, while UBT was the most accurate of the noninvasive methods and serology had a limited role in the management of H. pylori infection, due to its highly variable accuracy [74].
In Germany, the guidelines published by Fishbach et al. recognized all the diagnostic methods for H. pylori mentioned in this review [75].
Regarding the indications for H. pylori diagnosis, Fishbach et al. considered that gastric and duodenal ulcers or MALT lymphoma were absolute indications, while functional dyspepsia, cancer prevention, initiation of long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), or underlying gastroduodenal complications accompanied by the use of NSAIDs or acetylsalicylic acid were relative indications [75]. In addition, the international consensus recommendations for the management of patients with nonvariceal upper gastrointestinal bleeding included histology or UBT for the detection of H. pylori, 4–8 weeks from the bleeding episode and only if the initial index endoscopy was negative [76].
In Western Australia, Wise et al. reported that, UBT is one of the most accurate and reliable non-invasive methods for diagnosing active H. pylori infection [77].
In a study done on behalf of the EHMSG (European Helicobacter and Microbiota Study Group) and Consensus panel by Malfertheiner et al. concluded that, UBT is the most investigated and best recommended non-invasive test in the context of a “test-and-treat strategy”. Monoclonal SAT can also be used. Serological tests can be used only after validation. Rapid (“office”) serology tests using whole blood should be avoided in this regard. In clinical practice when there is an indication for endoscopy, and there is no contraindication for biopsy, the rapid urease test (RUT) is recommended as a first-line diagnostic test. In the case of a positive test, it allows immediate treatment. One biopsy should be taken from the corpus and one from the antrum. RUT is not recommended as a test for H. pylori eradication assessment after treatment. For assessment of H. pylori gastritis, a minimum standard biopsy setting is two biopsies from the antrum (greater and lesser curvature 3 cm proximal to the pyloric region) and two biopsies from the middle of the body. Additional biopsy from the incisura is considered for detection of precancerous lesions. Most cases of H. pylori infection can be diagnosed from gastric biopsies using histochemical staining alone. In cases of chronic (active) gastritis in which H. pylori is not detected by histochemistry, immunohistochemical testing of H. pylori can be used as an ancillary test. In the case of normal histology no immunohistochemical staining should be performed [78].
MENA region—Comparative studies of different diagnostic methods have been conducted locally and regionally, but to date, there are no local consensus guidelines.
In a 1996 study conducted in Jeddah, Saudi Arabia, Zaman et al. reported that most culture-positive samples also gave positive results in RUT (94%) [79]. However, they found that serology gave positive results for only 82% and 79% of the culture- and histology-positive samples, respectively. Therefore, serology was unreliable as a single diagnostic method. These findings were in contradiction with another study conducted at King Abdulaziz University Hospital in Jeddah, where Akbar et al. found that serology was more accurate to confirm positive results in histology-positive samples (n = 341) than RUT or culture [80]. However, this study also found that serology, RUT, and culture were less sensitive and specific diagnostic methods than histology. When compared to histology, the relative sensitivity of serology, RUT, and culture was 90%, 81%, and 63%, respectively, while their relative specificity was 47%, 92%, and 93%, respectively. In addition, Saber et al. reported that compared to PCR, the relative specificity and sensitivity of an anti-cagA IgG serologic test were 89.6% and 91.6%, respectively [81]. Serologic tests using serum and salivary were also considered in a study conducted in Abha, Saudi Arabia, by El-Mekki et al. [82]. The sensitivity of the serum and saliva tests was 90.5% and 95%, respectively, while their specificity was 84.5% and 70%, respectively. When they compared histology and culture, Zaman et al. found that 60% of the samples (n = 180) were culture-positive, while 87% were histology-positive [79]. More recently, a study conducted in Abha, Saudi Arabia, by Al Humayed et al. reported that culture and histology gave consistent results (whether positive or negative) in 97.4% of the cases (n = 115) [83]. In general, it appears that culture remains more sensitive and specific than histology, partly because the pathologist’s experience and other factors may affect the interpretation of the histologic samples.
The validity of SAT and UBT was only studied recently. In a study conducted in Abha, Al Humayed et al. compared the sensitivity and specificity of culture, SAT, histology, and RUT (CLOtest). They found that compared to culture, the relative sensitivity of SAT, histology, and RUT was 91.9%, 97.5%, and 79.7%, respectively, while their relative specificity was 98.6%, 97.2%, and 97.2%, respectively [83].
A study conducted in Riyadh, Saudi Arabia, by Al-Fadda et al. also compared different diagnostic methods and reported that compared to histology, the relative sensitivity of RUT and UBT was 88% and 85%, respectively, while their relative specificity was 87% and 70%, respectively. It is important to note that for histology the authors of this study used only one biopsy per patient (the gold standard of the study) [84].
In addition, a study conducted in Iran by Kazemi et al. reported surprisingly low values for the sensitivity (89%) and specificity (73%) of UBT [85]. However, the sensitivity and specificity of RUT (93% and 75%, respectively) and SAT (96% and 83%, respectively) appeared to be comparable to other studies. In this study, a patient was considered infected only if at least two diagnostic methods gave positive results. We believe that the low values for UBT could be attributed to methodological errors. In conclusion, this study recommended using SAT, rather than UBT, for the diagnosis of H. pylori infection in untreated patients, while pointing the need for follow-up studies. However, an additional Iranian study (n = 125) by Mansour-Ghanaei et al. found high specificity (100%) and sensitivity (94%) for UBT using radioactive 14C-urea [86].
In a study conducted in Saudi Arabia, Mohamed et al. compared three diagnostic methods for H. pylori: histology, RUT, and culture [87]. Altogether, H. pylori was identified by histology in 145 out of 196 cases (73.98%), while the urease test and culture gave positive results in 126 cases (64.29%) and 102 cases (52.04%), respectively.
There is even less literature on the performances of the different diagnostic methods for H. pylori in children. Studies conducted in Egypt by Frenck et al. (n = 108) and Iran by Falsafi et al. (n = 430) recommended using SAT and UBT, because of their high sensitivity (>90%) and specificity (>80%). However, they noted that while remaining high, SAT specificity was lower in children aged <6 years (81%) [88,89]. In comparison, these tests showed higher values in an Israeli study by Hino et al. (n = 92) (sensitivity and specificity of 97.5% and 94.7% for SAT, and 100% and 96.9% for UBT) [90]. Data about accuracy of diagnostic methods for H. pylori infection in MENA region are summarized (Table 2).
The available studies conducted in the MENA region and comparing several diagnostic methods did not apply a universal gold standard method for H. pylori diagnosis. Moreover, there was no record of a single study considering all the available diagnostic methods and, in most cases, the findings of the different studies were inconsistent. Therefore, further studies are needed to assess affordable, noninvasive diagnostic methods, which are particularly recommended for areas with high prevalence of H. pylori infection (like the MENA region). In addition, more attention should be paid to the methodology used in these future studies. For example, it is well-accepted that studies should consider the difference in the approach to diagnosis between children and adults and, therefore, future studies involving children must include noninvasive diagnostic methods. Finally, the existing guidelines from the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition or the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition are not applicable in areas with high prevalence of H. pylori infection, such as the MENA region, which further emphasize the need for new local guidelines [66].

4. Conclusions

The evidence presented in this review showed that H. pylori infection has a high prevalence in the MENA region, reaching extreme rates in several countries. H. pylori infection is usually contracted during the first years of life, and risk factors identified by studies across the region included lower socioeconomic status, level of education, age, contamination of food and water, and smoking.
Finally, the various diagnostic methods for H. pylori infection need to be carefully evaluated in well-designed studies, which has not been done in the MENA region. This approach will help in establishing cut-off values specific to each area and improving the diagnostic accuracy. Numerous studies and guidelines emphasize the importance of affordable, non-invasive diagnostic methods in developing countries with a high prevalence of H. pylori infection. Currently, the diagnostic methods available for screening in these areas include serology, UBT, and SAT. Moreover, tests based on novel antigens, such as FliD, could be used to improve the diagnostic accuracy. Due to the high prevalence of H. pylori infection in the MENA region and the role played by the bacteria in most gastroenterology cases, we highly recommend routine screening for H. pylori in all the patients admitted in gastroenterology clinics, which is in agreement with the World Gastroenterology Organization Global Guidelines established in 2011. Therefore, concerted effort from researchers and practitioners worldwide is required to establish affordable and accurate diagnostic methods for this purpose.

Author Contributions

Writing—Original Draft Preparation, A.M.A., M.I.K. and B.E.Y., M.A.E.; Writing—Review and Editing, F.A.S.A., Z.A.A., S.S.E. and M.A.E. All authors approved it for publication. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Fagoonee, S.; Pellicano, R. Helicobacter pylori: Molecular basis for colonization and survival in gastric environment and resistance to antibiotics. A short review. Infect. Dis. 2019, 51, 399–408. [Google Scholar] [CrossRef] [PubMed]
  2. Vandamme, P.; Falsen, E.; Rossau, R.; Hoste, B.; Segers, P.; Tytgat, R.; De Ley, J. Revision of Campylobacter, Helicobacter, and Wolinella taxonomy: Emendation of generic descriptions and proposal of Arcobacter gen. nov. Int. J. Syst. Bacteriol. 1991, 41, 88–103. [Google Scholar] [CrossRef] [PubMed][Green Version]
  3. Goodwin, C.; McCulloch, R.; Armstrong, J.; Wee, S. Unusual cellular fatty acids and distinctive ultrastructure in a new spiral bacterium (Campylobacter pyloridis) from the human gastric mucosa. J. Med. Microbiol. 1985, 19, 257–267. [Google Scholar] [CrossRef] [PubMed]
  4. Bizzozero, G. Ueber die schlauchförmigen Drüsen des Magendarmkanals und die Beziehungen ihres Epithels zu dem Oberflächenepithel der Schleimhaut Dritte Mittheilung. Arch. Mikrosk. Anat. 1893, 42, 82–152. [Google Scholar] [CrossRef][Green Version]
  5. Janulaityte-Gunther, D.; Gunther, T.; Pavilonis, A.; Kupcinskas, L. What Bizzozero never could imagine-Helicobacter pylori today and tomorrow. Medicina 2003, 39, 542–549. [Google Scholar]
  6. Jaworski, W. Podrêcznik Chorób Zoladka (Handbook of Gastric Diseases); Wydawnictwa Dziel Lekarskich Polskich: Krakow, Poland, 1899; pp. 30–47. [Google Scholar]
  7. Konturek, P.C.; Konturek, S.J.; Brzozowski, T. Helicobacter pylori infection in gastric cancerogenesis. J. Physiol. Pharm. Off. J. Pol. Physiol. Soc. 2009, 60, 3–21. [Google Scholar]
  8. Marshall, B.; Warren, J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984, 323, 1311–1315. [Google Scholar] [CrossRef]
  9. Schreiber, S.; Konradt, M.; Groll, C.; Scheid, P.; Hanauer, G.; Werling, H.-O.; Josenhans, C.; Suerbaum, S. The spatial orientation of Helicobacter pylori in the gastric mucus. Proc. Natl. Acad. Sci. USA 2004, 101, 5024–5029. [Google Scholar] [CrossRef][Green Version]
  10. Isaeva, G.S.; Fagoonee, S. Biological properties and pathogenicity factors of Helicobacter pylori. Minerva Gastroenterol. Dietol. 2018, 64, 255–266. [Google Scholar] [CrossRef]
  11. Chang, A.H.; Parsonnet, J. Role of bacteria in oncogenesis. Clin. Microbiol. Rev. 2010, 23, 837–857. [Google Scholar] [CrossRef] [PubMed][Green Version]
  12. Etemadi, A.; Safiri, S.; Sepanlou, S.G.; Ikuta, K.; Bisignano, C.; Shakeri, R.; Amani, M.; Fitzmaurice, C.; Nixon, M.; Abbasi, N.; et al. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: A systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol. Hepatol. 2020, 5, 42–54. [Google Scholar] [CrossRef][Green Version]
  13. Cheng, H.; Hu, F.; Zhang, L.; Yang, G.; Ma, J.; Hu, J.; Wang, W.; Gao, W.; Dong, X. Prevalence of Helicobacter pylori infection and identification of risk factors in rural and urban Beijing, China. Helicobacter 2009, 14, 128–133. [Google Scholar] [CrossRef] [PubMed]
  14. Mentis, A.; Lehours, P.; Mégraud, F. Epidemiology and Diagnosis of Helicobacter pylori infection. Helicobacter 2015, 20, 1–7. [Google Scholar] [CrossRef] [PubMed][Green Version]
  15. Hooi, J.K.; Lai, W.Y.; Ng, W.K.; Suen, M.M.; Underwood, F.E.; Tanyingoh, D.; Malfertheiner, P.; Graham, D.Y.; Wong, V.W.; Wu, J.C. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology 2017, 153, 420–429. [Google Scholar] [CrossRef] [PubMed][Green Version]
  16. Gilboa, S.; Gabay, G.; Zamir, D.; Zeev, A.; Novis, B. Helicobacter pylori infection in rural settlements (Kibbutzim) in Israel. Int. J. Epidemiol. 1995, 24, 232–237. [Google Scholar] [CrossRef] [PubMed]
  17. Mohammad, M.A.; Hussein, L.; Coward, A.; Jackson, S.J. Prevalence of Helicobacter pylori infection among Egyptian children: Impact of social background and effect on growth. Public Health Nutr. 2008, 11, 230–236. [Google Scholar] [CrossRef][Green Version]
  18. Salem, O.; Youssri, A.; Mohammad, O. The prevalence of H. pylori antibodies in asymptomatic young egyptian persons. J. Egypt. Public Health Assoc. 1993, 68, 333–352. [Google Scholar]
  19. Bassily, S.; Frenck, R.W.; Mohareb, E.W.; Wierzba, T.; Savarino, S.; Hall, E.; Kotkat, A.; Naficy, A.; Hyams, K.C.; Clemens, J. Seroprevalence of Helicobacter pylori among Egyptian newborns and their mothers: A preliminary report. Am. J. Trop. Med. Hyg. 1999, 61, 37–40. [Google Scholar] [CrossRef][Green Version]
  20. Alborzi, A.; Soltani, J.; Pourabbas, B.; Oboodi, B.; Haghighat, M.; Hayati, M.; Rashidi, M. Prevalence of Helicobacter pylori infection in children (south of Iran). Diagn. Microbiol. Infect. Dis. 2006, 54, 259–261. [Google Scholar] [CrossRef]
  21. Mansour-Ghanaei, F.; Mashhour, M.Y.; Joukar, F.; Sedigh, M.; Bagher-Zadeh, A.; Jafarshad, R. Prevalence of Helicobacter pylori infection among children in Rasht, Northern Iran. Middle East J. Dig. Dis. MEJDD 2009, 1, 84–88. [Google Scholar]
  22. Soltani, J.; Amirzadeh, J.; Nahedi, S.; Shahsavari, S. Prevalence of Helicobacter pylori infection in children, a population-based cross-sectional study in west iran. Iran. J. Pediatr. 2013, 23, 13–18. [Google Scholar]
  23. Afsharipour, S.; Nazari, R.; Douraghi, M. Seroprevalence of anti-Helicobacter pylori and anti-cytotoxin-associated gene A antibodies among healthy individuals in center of Iran. Iran. J. Basic Med. Sci. 2014, 17, 547–552. [Google Scholar]
  24. Salehi, M.; Ghasemian, A.; Mostafavi, S.K.S.; Najafi, S.; Vardanjani, H.R. Sero-prevalence of Helicobacter pylori infection in Neyshabur, Iran, during 2010–2015. Iran. J. Pathol. 2017, 12, 183–188. [Google Scholar]
  25. Shuval-Sudai, O.; Granot, E. An association between Helicobacter pylori infection and serum vitamin B12 levels in healthy adults. J. Clin. Gastroenterol. 2003, 36, 130–133. [Google Scholar] [CrossRef]
  26. Muhsen, K.; Cohen, D.; Spungin-Bialik, A.; Shohat, T. Seroprevalence, correlates and trends of Helicobacter pylori infection in the Israeli population. Epidemiol. Infect. 2012, 140, 1207–1214. [Google Scholar] [CrossRef]
  27. Naous, A.; Al-Tannir, M.; Naja, Z.; Ziade, F.; El-Rajab, M. Fecoprevalence and determinants of Helicobacter pylori infection among asymptomatic children in Lebanon. J. Med. Liban. 2007, 55, 138–144. [Google Scholar]
  28. Bakka, A.S.; Salih, B.A. Prevalence of Helicobacter pylori infection in asymptomatic subjects in Libya. Diagn. Microbiol. Infect. Dis. 2002, 43, 265–268. [Google Scholar] [CrossRef]
  29. Al-Balushi, M.S.; Al-Busaidi, J.Z.; Al-Daihani, M.S.; Shafeeq, M.O.; Hasson, S.S. Sero-prevalence of Helicobacter pylori infection among asymptomatic healthy Omani blood donors. Asian Pac. J. Trop. Dis. 2013, 3, 146–149. [Google Scholar] [CrossRef]
  30. Al-Moagel, M.A.; Evans, D.G.; Abdulghani, M.; Adam, E.; Evans Jr, D.J.; Malaty, H.M.; Graham, D.Y. Prevalence of Helicobacter (formerly Campylobacter) pylori infection in Saudia Arabia, and comparison of those with and without upper gastrointestinal symptoms. Am. J. Gastroenterol. 1990, 85, 944–948. [Google Scholar]
  31. Al-Knawy, B.; Ahmed, M.-E.K.; Mirdad, S.; ElMekki, A.; Al-Ammari, O. Intrafamillial Clustering of Helicobacter pylori Infection in Saubi Arabia. Can. J. Gastroenterol. 2000, 14, 772–774. [Google Scholar] [CrossRef][Green Version]
  32. Khan, M.A.; Ghazi, H.O. Helicobacter pylori infection in asymptomatic subjects in Makkah, Saudi Arabia. J. Pak. Med. Assoc. 2007, 57, 114–117. [Google Scholar]
  33. Telmesani, A.M. Helicobacter pylori: Prevalence and relationship with abdominal pain in school children in Makkah City, western Saudi Arabia. Saudi J. Gastroenterol. 2009, 15, 100–103. [Google Scholar] [CrossRef]
  34. Habib, H.S.; Hegazi, M.A.; Murad, H.A.; Amir, E.M.; Halawa, T.F.; El-Deek, B.S. Unique features and risk factors of Helicobacter pylori infection at the main children’s intermediate school in Rabigh, Saudi Arabia. Indian J. Gastroenterol. 2014, 33, 375–382. [Google Scholar] [CrossRef]
  35. Hanafi, M.I.; Mohamed, A.M. Helicobacter pylori infection: Seroprevalence and predictors among healthy individuals in Al Madinah, Saudi Arabia. J. Egypt. Public Health Assoc. 2013, 88, 40–45. [Google Scholar] [CrossRef]
  36. Hunt, R.; Xiao, S.; Megraud, F.; Leon-Barua, R.; Bazzoli, F.; Van der Merwe, S.; Vaz Coelho, L.; Fock, M.; Fedail, S.; Cohen, H. Helicobacter pylori in developing countries. World gastroenterology organisation global guideline. J. Gastrointestin Liver Dis. 2011, 20, 299–304. [Google Scholar]
  37. Ben, A.A.; Cheikh, I.; Kchaou, M.; Chouaib, S.; Ouerghi, H.; Chaâbouni, H. Prevalence of Helicobacter pylori infection in normal or asymptomatic patients. Tunis Med. 2003, 81, 200–204. [Google Scholar]
  38. Hasosah, M.; Satti, M.; Shehzad, A.; Alsahafi, A.; Sukkar, G.; Alzaben, A.; Sunaid, A.; Ahmed, A.; AlThubiti, S.; Mufti, A. Prevalence and Risk Factors of Helicobacter pylori Infection in Saudi Children: A Three-Year Prospective Controlled Study. Helicobacter 2015, 20, 56–63. [Google Scholar] [CrossRef]
  39. Bajaj, S.; Rekwal, L.; Misra, S.; Misra, V.; Yadav, R.K.; Srivastava, A. Association of Helicobacter pylori infection with type 2 diabetes. Indian J. Endocrinol. Mtab. 2014, 18, 694–699. [Google Scholar]
  40. Gunaid, A.A.; Hassan, N.A.; Murray-Lyon, I. Prevalence and risk factors for Helicobacter pylori infection among Yemeni dyspeptic patients. Saudi Med. J. 2003, 24, 512–517. [Google Scholar]
  41. Van Doorn, L.J.; Figueiredo, C.; Mégraud, F.; Pena, S.; Midolo, P.; Queiroz, D.M.D.M.; Carneiro, F.; Vanderborght, B.; Maria Da Glória, F.P.; Sanna, R. Geographic distribution of vacA allelic types of Helicobacter pylori. Gastroenterology 1999, 116, 823–830. [Google Scholar] [CrossRef]
  42. Sugimoto, M.; Zali, M.; Yamaoka, Y. The association of vacA genotypes and Helicobacter pylori-related gastroduodenal diseases in the Middle East. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28, 1227–1236. [Google Scholar] [CrossRef][Green Version]
  43. Al Qabandi, A.; Mustafa, A.; Siddique, I.; Khajah, A.; Madda, J.; Junaid, T. Distribution of vacA and cagA genotypes of Helicobacter pylori in Kuwait. Acta Trop. 2005, 93, 283–288. [Google Scholar] [CrossRef]
  44. Muhsen, K.; Sinnereich, R.; Beer-Davidson, G.; Nassar, H.; Ahmed, W.A.; Cohen, D.; Kark, J.D. Correlates of infection with Helicobacter pylori positive and negative cytotoxin-associated gene A phenotypes among Arab and Jewish residents of Jerusalem. Epidemiol. Infect. 2019, 147, e276. [Google Scholar] [CrossRef][Green Version]
  45. Genta, R.M.; Graham, D.Y. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: A topographic study of H. pylori density and distribution. Gastrointest. Endosc. 1994, 40, 342–345. [Google Scholar] [CrossRef]
  46. Satoh, K.; Kimura, K.; Taniguchi, Y.; Kihira, K.; Takimoto, T.; Saifuku, K.; Kawata, H.; Tokumaru, K.; Kojima, T.; Seki, M. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am. J. Gastroenterol. 1998, 93, 569–573. [Google Scholar] [CrossRef]
  47. Van Ijzendoorn, M.; Laheij, R.; De Boer, W.; Jansen, J. The importance of corpus biopsies for the determination of Helicobacter pylori infection. Neth. J. Med. 2005, 63, 141–145. [Google Scholar]
  48. Lan, H.-C.; Chen, T.-S.; Li, A.F.-Y.; Chang, F.-Y.; Lin, H.-C. Additional corpus biopsy enhances the detection of Helicobacter pylori infection in a background of gastritis with atrophy. BMC Gastroenterol. 2012, 12, 182. [Google Scholar] [CrossRef][Green Version]
  49. Dixon, M.F.; Genta, R.M.; Yardley, J.H.; Correa, P. Classification and grading of gastritis: The updated Sydney system. Am. J. Surg. Pathol. 1996, 20, 1161–1181. [Google Scholar] [CrossRef]
  50. El-Zimaity, H.M.; Graham, D.Y. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: Role of the Sydney System. Hum. Pathol. 1999, 30, 72–77. [Google Scholar] [CrossRef]
  51. Stolte, M.; Meining, A. The updated Sydney system: Classification and grading of gastritis as the basis of diagnosis and treatment. Can. J. Gastroenterol. Hepatol. 2001, 15, 591–598. [Google Scholar] [CrossRef] [PubMed][Green Version]
  52. Garza-González, E.; Perez-Perez, G.I.; Maldonado-Garza, H.J.; Bosques-Padilla, F.J. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J. Gastroenterol. 2014, 20, 1438–1449. [Google Scholar] [CrossRef] [PubMed]
  53. Trebesius, K.; Panthel, K.; Strobel, S.; Vogt, K.; Faller, G.; Kirchner, T.; Kist, M.; Heesemann, J.; Haas, R. Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation. Gut 2000, 46, 608–614. [Google Scholar] [CrossRef] [PubMed][Green Version]
  54. Rüssmann, H.; Kempf, V.A.; Koletzko, S.; Heesemann, J.; Autenrieth, I.B. Comparison of fluorescent in situ hybridization and conventional culturing for detection of Helicobacter pylori in gastric biopsy specimens. J. Clin. Microbiol. 2001, 39, 304–308. [Google Scholar] [CrossRef] [PubMed][Green Version]
  55. Camorlinga-Ponce, M.; Romo, C.; Gonzalez-Valencia, G.; Munoz, O.; Torres, J. Topographical localisation of cagA positive and cagA negative Helicobacter pylori strains in the gastric mucosa; an in situ hybridisation study. J. Clin. Pathol. 2004, 57, 822–828. [Google Scholar] [CrossRef][Green Version]
  56. Windsor, H.M.; Abioye-Kuteyi, E.A.; Marshall, B.J. Methodology and transport medium for collection of Helicobacter pylori on a string test in remote locations. Helicobacter 2005, 10, 630–634. [Google Scholar] [CrossRef]
  57. Velapatino, B.; Balqui, J.; Gilman, R.H.; Bussalleu, A.; Quino, W.; Finger, S.A.; Santivanez, L.; Herrera, P.; Piscoya, A.; Valdivia, J. Validation of string test for diagnosis of Helicobacter pylori infections. J. Clin. Microbiol. 2006, 44, 976–980. [Google Scholar] [CrossRef][Green Version]
  58. Hirschl, A.M.; Makristathis, A. Methods to detect Helicobacter pylori: From culture to molecular biology. Helicobacter 2007, 12, 6–11. [Google Scholar] [CrossRef]
  59. Choi, Y.J.; Kim, N.; Lim, J.; Jo, S.Y.; Shin, C.M.; Lee, H.S.; Lee, S.H.; Park, Y.S.; Hwang, J.H.; Kim, J.W. Accuracy of diagnostic tests for Helicobacter pylori in patients with peptic ulcer bleeding. Helicobacter 2012, 17, 77–85. [Google Scholar] [CrossRef]
  60. Mendoza-Ibarra, S.I.; Perez-Perez, G.I.; Bosques-Padilla, F.J.; Urquidi-Rivera, M.; Rodriguez-Esquivel, Z.; Garza-Gonzalez, E. Utility of diagnostic tests for detection of Helicobacter pylori in children in northeastern Mexico. Pediatr. Int. 2007, 49, 869–874. [Google Scholar] [CrossRef]
  61. Ndip, R.N.; MacKay, W.G.; Farthing, M.J.; Weaver, L.T. Culturing Helicobacter pylori from clinical specimens: Review of microbiologic methods. J. Pediatr. Gastroenterol. Nutr. 2003, 36, 616–622. [Google Scholar] [CrossRef] [PubMed][Green Version]
  62. Owen, R. Molecular testing for antibiotic resistance in Helicobacter pylori. Gut 2002, 50, 285–289. [Google Scholar] [CrossRef] [PubMed][Green Version]
  63. Monteiro, L.; De Mascarel, A.; Sarrasqueta, A.M.; Bergey, B.; Barberis, C.; Talby, P.; Roux, D.; Shouler, L.; Goldfain, D.; Lamouliatte, H. Diagnosis of Helicobacter pylori infection: Noninvasive methods compared to invasive methods and evaluation of two new tests. Am. J. Gastroenterol. 2001, 96, 353–358. [Google Scholar] [CrossRef] [PubMed]
  64. Yunoki, N.; Yokota, K.; Mizuno, M.; Kawahara, Y.; Adachi, M.; Okada, H.; Hayashi, S.; Hirai, Y.; Oguma, K.; Tsuji, T. Antibody to heat shock protein can be used for early serological monitoring of Helicobacter pylori eradication treatment. Clin. Diag. Lab. Immunol. 2000, 7, 574–577. [Google Scholar] [CrossRef] [PubMed][Green Version]
  65. Hirschl, A.; Rotter, M. Serological tests for monitoring Helicobacter pylori eradication treatment. J. Gastroenterol. 1996, 31, 33–36. [Google Scholar]
  66. Somily, A.M.; Morshed, M. An update of laboratory diagnosis of Helicobacter pylori in the Kingdom of Saudi Arabia. J. Infect. Dev. Ctries 2015, 9, 806–814. [Google Scholar] [CrossRef][Green Version]
  67. Gisbert, J.; Pajares, J. 13C-urea breath test in the diagnosis of Helicobacter pylori infection–a critical review. Aliment. Pharmacol. Ther. 2004, 20, 1001–1017. [Google Scholar] [CrossRef]
  68. Capurso, G.; Carnuccio, A.; Lahner, E.; Panzuto, F.; Baccini, F.; Fave, G.; Annibale, B. Corpus-predominant gastritis as a risk factor for false-negative 13C-urea breath test results. Aliment. Pharmacol. Ther. 2006, 24, 1453–1460. [Google Scholar] [CrossRef]
  69. Graham, D.Y.; Klein, P.D. Accurate diagnosis of Helicobacter pylori: 13C-urea breath test. Gastroenterol. Clin. North. Am. 2000, 29, 885–893. [Google Scholar] [CrossRef]
  70. Gisbert, J.P.; Pajares, J.M. Stool antigen test for the diagnosis of Helicobacter pylori infection: A systematic review. Helicobacter 2004, 9, 347–368. [Google Scholar] [CrossRef]
  71. Gisbert, J.P.; de la Morena, F.; Abraira, V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: A systematic review and meta-analysis. Am. J. Gastroenterol. 2006, 101, 1921–1930. [Google Scholar] [CrossRef] [PubMed]
  72. Gholi, M.K.; Kalali, B.; Formichella, L.; Göttner, G.; Shamsipour, F.; hassan Zarnani, A.; Hosseini, M.; Busch, D.H.; Shirazi, M.H.; Gerhard, M. Helicobacter pylori FliD protein is a highly sensitive and specific marker for serologic diagnosis of H. pylori infection. Int. J. Med. Microbiol. 2013, 303, 618–623. [Google Scholar] [CrossRef] [PubMed]
  73. Asaka, M.; Kato, M.; Takahashi, S.I.; Fukuda, Y.; Sugiyama, T.; Ota, H.; Uemura, N.; Murakami, K.; Satoh, K.; Sugano, K. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010, 15, 1–20. [Google Scholar] [CrossRef] [PubMed]
  74. Fock, K.M.; Katelaris, P.; Sugano, K.; Ang, T.L.; Hunt, R.; Talley, N.J.; Lam, S.K.; Xiao, S.D.; Tan, H.J.; Wu, C.Y. Second Asia–Pacific consensus guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2009, 24, 1587–1600. [Google Scholar] [CrossRef] [PubMed]
  75. Fischbach, W.; Malfertheiner, P.; Hoffmann, J.; Bolten, W.; Bornschein, J.; Götze, O.; Höhne, W.; Kist, M.; Koletzko, S.; Labenz, J. S3-Guideline “Helicobacter pylori and gastroduodenal ulcer disease” of the German Society for Digestive and Metabolic Diseases (DGVS) in cooperation with the German Society for Hygiene and Microbiology, Society for Pediatric Gastroenterology and Nutrition e. V., German Society for Rheumatology, AWMF-Registration-no. 021/001. Z. Gastroenterol. 2009, 47, 1230–1263. [Google Scholar] [PubMed]
  76. Barkun, A.N.; Bardou, M.; Kuipers, E.J.; Sung, J.; Hunt, R.H.; Martel, M.; Sinclair, P. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann. Intern. Med. 2010, 152, 101–113. [Google Scholar] [CrossRef][Green Version]
  77. Wise, M.J.; Lamichhane, B.; Webberley, K.M. A Longitudinal, Population-Level, Big-Data Study of Helicobacter pylori-Related Disease across Western Australia. J. Clin. Med. 2019, 8, 1821. [Google Scholar] [CrossRef][Green Version]
  78. Malfertheiner, P.; Megraud, F.; O’morain, C.A.; Gisbert, J.P.; Kuipers, E.J.; Axon, A.T.; Bazzoli, F.; Gasbarrini, A.; Atherton, J.; Graham, D.Y.; et al. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut. 2017, 66, 6–30. [Google Scholar] [CrossRef][Green Version]
  79. Zaman, R.; Hossain, J.; Zawawi, T.H.; Thomas, J.; Gilpin, C.; Dibb, W.L. Diagnosis of Helicobacter pylori infection: A study in the western province of Saudi Arabia. Saudi Med. J. 1995, 16, 552–555. [Google Scholar]
  80. Akbar, D.H.; Eltahawy, A.T.A. Helicobacter pylori infection at a university hospital in Saudi Arabia: Prevalence, comparison of diagnostic modalities and endoscopic findings. Indian J. Pathol. Microbiol. 2005, 48, 181–185. [Google Scholar]
  81. Saber, T.; Ghonaim, M.M.; Yousef, A.R.; Khalifa, A.; Al Qurashi, H.; Shaqhan, M.; Samaha, M. Association of Helicobacter pylori cagA gene with gastric cancer and peptic ulcer in saudi patients. J. Microbiol. Biotechnol. 2015, 25, 1146–1153. [Google Scholar] [CrossRef] [PubMed]
  82. El-Mekki, A.; Kumar, A.; Alknawy, B.; Al-Ammari, O.; Moosa, R.; Quli, S.; Ahmed, M. Comparison of enzyme immunoassays detecting Helicobacter pylori specific IgG in serum and saliva with endoscopic and biopsy findings in patients with dyspepsia. Indian J. Med. Microbiol. 2011, 29, 136–140. [Google Scholar] [PubMed]
  83. Al-Humayed, S.M.; Ahmed, E.K.; Bello, C.S.; Mar’I A, T. Comparison of 4 laboratory methods for detection of Helicobacter pylori. Saudi Med. J. 2008, 29, 530–532. [Google Scholar] [PubMed]
  84. Al-Fadda, M.; Powe, J.; Rezeig, M.; Al Nazer, M.; Alrajhi, A.A.; Baynton, R. Comparison of carbon-14-urea breath test and rapid urease test with gastric biopsy for identification of Helicobacter pylori. Ann. Saudi Med. 2000, 20, 170–172. [Google Scholar] [CrossRef][Green Version]
  85. Kazemi, S.; Tavakkoli, H.; Habizadeh, M.R.; Emami, M.H. Diagnostic values of Helicobacter pylori diagnostic tests: Stool antigen test, urea breath test, rapid urease test, serology and histology. J. Res. Med. Sci. 2011, 16, 1097–2104. [Google Scholar]
  86. Mansour-Ghanaei, F.; Sanaei, O.; Joukar, F. Clinical Validation of an Office-Based 14C-UBT (Heliprobe) for H. pylori Diagnosis in Iranian Dyspeptic Patients. Gastroenterol. Res. Pract. 2011, 2011, 930941. [Google Scholar]
  87. Mohamed, A.; Al Karawi, A.; Al Jumah, A.; Ahmed, A.; Sharig, S.; Yasawy, M.; Osaba, O. Helicobacter pylori: Incidence and comparison of three diagnostic methods in 196 Saudi patients with dyspepsia. Hepatogastroenterology 1994, 41, 48–50. [Google Scholar]
  88. Frenck, R.W.; Fathy, H.M.; Sherif, M.; Mohran, Z.; El Mohammedy, H.; Francis, W.; Rockabrand, D.; Mounir, B.I.; Rozmajzl, P.; Frierson, H.F. Sensitivity and specificity of various tests for the diagnosis of Helicobacter pylori in Egyptian children. Pediatrics 2006, 118, e1195–e1202. [Google Scholar] [CrossRef]
  89. Falsafi, T.; Valizadeh, N.; Sepehr, S.; Najafi, M. Application of a stool antigen test to evaluate the incidence of Helicobacter pylori infection in children and adolescents from Tehran, Iran. Clin. Diag. Lab. Immun. 2005, 12, 1094–1097. [Google Scholar] [CrossRef][Green Version]
  90. Hino, B.; Eliakim, R.; Levine, A.; Sprecher, H.; Berkowitz, D.; Hartman, C.; Eshach-Adiv, O.; Shamir, R. Comparison of invasive and non-invasive tests diagnosis and monitoring of Helicobacter pylori infection in children. J. Pediatr. Gastroenterol. Nutr. 2004, 39, 519–523. [Google Scholar] [CrossRef]
Table
Table 1. Prevalence of H. pylori in Middle East and North Africa (MENA) region and the used diagnostic method.
Table 1. Prevalence of H. pylori in Middle East and North Africa (MENA) region and the used diagnostic method.
RegionSample Size (n)Positive Cases (%)Method of Detecting H. pyloriStudy
Egypt286207 (72.38%)Serum IgG (ELISA)[17]
8978 (87.6%)Serum IgG (ELISA)[18]
1910 (53%)Serum IgG (ELISA)
2929 (100%)
4139 (95%)
16942 (25%)Serum IgG (ELISA)[19]
169149 (88%)
Iran593488 (82%)Stool antigen (ELISA)[20]
961384 (40%)Stool antigen (ELISA)[21]
458294 (64.2%)Stool antigen (ELISA)[22]
525390 (74.2%)Serum IgG (ELISA)[23]
11596628 (5.3%)Serum IgA (ELISA)[24]
4500 (38.8%)Serum IgG (ELISA)
442 (7.2%)Serum IgM (ELISA)
Israel377271 (72%)Serum IgG (ELISA)[25]
2093 Jewish946 (45.2%)Serum IgG (ELISA)[26]
1472 Arabs619 (42.1%)
Lebanon41487(21%)Stool antigen[27]
Libya360275 (76%)Serum IgG (ELISA)[28]
Oman13391 (68.4%)Serum IgA, IgM & IgG (ELISA)[29]
Saudi Arabia577380 (66%)Serum IgG (ELISA)[30]
355134 (37.7%)Saliva IgG[31]
396201 (51%)Serum IgG (ELISA)[32]
31486 (27.4%)Urea breath test[33]
13268 (51.5%)Urea breath test[34]
70 (53%)Serum IgG (ELFA)
456129 (28.3%)Serum IgG (ELISA)[35]
N/A40%Serum IgG (ELISA)[36]
Tunisia9881 (82.7%)N/A[37]
IgG: immunoglobulin G; IgA: immunoglobulin A; IgM: immunoglobulin M; ELISA: enzyme-linked immunosorbent assay; ELFA: enzymelinked flourescence assay; N/A: not applicable.
Table
Table 2. Diagnostic methods used for H. pylori infection in MENA region.
Table 2. Diagnostic methods used for H. pylori infection in MENA region.
MethodsSample SizeSensitivity & Specificity
Histology-Ranges (53–90%)
11597.5% sensitivity
97.2% Specificity
Fluorescent in-situ hybridization (FISH)27100%
Culture->90% sensitivity
100% specificity
34163% sensitivity
93% specificity
Rapid urease test (RUT)10485–95% sensitivity
95–100% specificity
34192% Sensitivity
81% specificity
11579.7% sensitivity
97.2% specificity
6488% Sensitivity
87% specificity
9493% Sensitivity
75% specificity
Enzyme immunoassay (EIA) Ranges (60–100%)
34190% Sensitivity
47% Specificity
Urea breath test (UBT)->95%
6485% Sensitivity
70% specificity
9489% Sensitivity
73% specificity
12594% Sensitivity
100% Specificity
196Sensitivity 64.29%
108>80% sensitivity
>90% specificity
430
Stool antigen test (SAT)108>80% sensitivity
>90% specificity
430
-(48.9–100%) sensitivity
(87–94.4%) specificity
11591.9% sensitivity
97.6% specificity
9496% sensitivity
83% specificity

Share and Cite

MDPI and ACS Style

Alsulaimany, F.A.S.; Awan, Z.A.; Almohamady, A.M.; Koumu, M.I.; Yaghmoor, B.E.; Elhady, S.S.; Elfaky, M.A. Prevalence of Helicobacter pylori Infection and Diagnostic Methods in the Middle East and North Africa Region. Medicina 2020, 56, 169. https://doi.org/10.3390/medicina56040169

AMA Style

Alsulaimany FAS, Awan ZA, Almohamady AM, Koumu MI, Yaghmoor BE, Elhady SS, Elfaky MA. Prevalence of Helicobacter pylori Infection and Diagnostic Methods in the Middle East and North Africa Region. Medicina. 2020; 56(4):169. https://doi.org/10.3390/medicina56040169

Chicago/Turabian Style

Alsulaimany, Faten A. S., Zuhier A. Awan, Ahmad M. Almohamady, Mohammed I. Koumu, Bassam E. Yaghmoor, Sameh S. Elhady, and Mahmoud A. Elfaky. 2020. "Prevalence of Helicobacter pylori Infection and Diagnostic Methods in the Middle East and North Africa Region" Medicina 56, no. 4: 169. https://doi.org/10.3390/medicina56040169

Article Metrics

Back to TopTop